Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Long-Term Investments: 2010-2024

Historic Long-Term Investments for Cytokinetics (CYTK) over the last 11 years, with Dec 2024 value amounting to $145.1 million.

  • Cytokinetics' Long-Term Investments rose 7.30% to $288.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.8 million, marking a year-over-year increase of 7.30%. This contributed to the annual value of $145.1 million for FY2024, which is 257.86% up from last year.
  • Cytokinetics' Long-Term Investments amounted to $145.1 million in FY2024, which was up 257.86% from $40.5 million recorded in FY2023.
  • Cytokinetics' Long-Term Investments' 5-year high stood at $152.1 million during FY2021, with a 5-year trough of $37.0 million in FY2020.
  • For the 3-year period, Cytokinetics' Long-Term Investments averaged around $77.4 million, with its median value being $46.7 million (2022).
  • Its Long-Term Investments has fluctuated over the past 5 years, first spiked by 311.46% in 2021, then tumbled by 69.28% in 2022.
  • Over the past 5 years, Cytokinetics' Long-Term Investments (Yearly) stood at $37.0 million in 2020, then skyrocketed by 311.46% to $152.1 million in 2021, then slumped by 69.28% to $46.7 million in 2022, then decreased by 13.22% to $40.5 million in 2023, then surged by 257.86% to $145.1 million in 2024.